20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
4D Molecular Therapeutics Inc (FDMT) operates in the BIOTECHNOLOGY industry and is headquartered in EmeryVille, United States with about 196 employees. Its market capitalization is roughly $779 million. In the fiscal year ended 2025-12-31, FDMT reported $85M in revenue and ($140M) in net income.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
Interactive charts & full statements → Open the FDMT valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $92M | $85M | $0M | $21M | $3M | $18M | $14M | $7M | $14M | $6M |
| Gross Profit | $39M | $78M | ($141M) | ($76M) | $3M | $18M | ($39M) | ($32M) | ($4M) | ($8M) |
| Gross Margin % | 42.0% | 91.0% | -381789.2% | -368.5% | 100.0% | 100.0% | -289.6% | -454.2% | -29.9% | -134.4% |
| Operating Income (EBIT) | ($197M) | ($160M) | ($188M) | ($113M) | ($110M) | ($71M) | ($57M) | ($51M) | ($10M) | ($11M) |
| Operating Margin % | -214.2% | -187.2% | -507678.4% | -544.7% | -3516.5% | -395.5% | -416.3% | -726.6% | -73.6% | -194.7% |
| Net Income | ($179M) | ($140M) | ($161M) | ($101M) | ($101M) | ($68M) | ($57M) | ($49M) | ($10M) | ($11M) |
| Net Margin % | -194.7% | -164.4% | -434778.4% | -486.6% | -3230.3% | -378.6% | -416.5% | -705.8% | -67.6% | -193.8% |
| EBITDA | ($185M) | ($132M) | ($154M) | ($97M) | ($106M) | ($68M) | ($55M) | ($45M) | ($10M) | ($11M) |
| Earnings Per Share (EPS) | $-2.73 | $-2.42 | $-2.98 | $-2.58 | $-3.12 | $-2.46 | $-2.12 | $-1.86 | $-0.76 | $-0.76 |
| Shares Outstanding (M) | 70M | 58M | 54M | 39M | 32M | 28M | 27M | 26M | 13M | 15M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $4M | $3M | $85M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $2M | $1M | $83M | ($47M) | ($48M) | ($41M) | ($2M) | ($38M) |
| Gross Margin % | 44.8% | 32.6% | 97.7% | -52386.7% | -319573.3% | -290607.1% | -178300.0% | -1282700.0% |
| Operating Income (EBIT) | ($77M) | ($74M) | $15M | ($61M) | ($59M) | ($54M) | ($56M) | ($51M) |
| Operating Margin % | -2037.2% | -2416.2% | 17.3% | -67983.3% | -396373.3% | -383007.1% | -5611700.0% | -1704400.0% |
| Net Income | ($73M) | ($69M) | $19M | ($57M) | ($55M) | ($48M) | ($50M) | ($44M) |
| Net Margin % | -1929.0% | -2256.7% | 22.8% | -63195.6% | -364386.7% | -342657.1% | -4967100.0% | -1461433.3% |
| EBITDA | ($75M) | ($67M) | $12M | ($56M) | ($53M) | ($46M) | ($48M) | ($42M) |
| Earnings Per Share (EPS) | $-1.04 | $-1.01 | $0.33 | $-1.01 | $-0.98 | $-0.86 | $-0.92 | $-0.79 |
| Shares Outstanding (M) | 70M | 68M | 58M | 56M | 56M | 56M | 54M | 56M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($156M) | ($109M) | ($135M) | ($76M) | ($87M) | ($69M) | ($51M) | ($37M) | ($16M) | $8M |
| Capital Expenditures (CapEx) | $1M | $1M | $4M | $3M | $12M | $9M | $1M | $3M | $0M | $1M |
| Free Cash Flow (FCF) | ($157M) | ($110M) | ($138M) | ($79M) | ($98M) | ($78M) | ($52M) | ($40M) | ($17M) | $8M |
| FCF Margin % | -170.5% | -128.7% | -373975.7% | -379.1% | -3139.0% | -433.8% | -381.3% | -571.3% | -118.0% | 132.4% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($70M) | ($68M) | $29M | ($46M) | ($43M) | ($48M) | ($46M) | ($29M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M | $1M | $1M | $2M |
| Free Cash Flow (FCF) | ($70M) | ($68M) | $28M | ($47M) | ($43M) | ($48M) | ($47M) | ($31M) |
| FCF Margin % | -1852.8% | -2235.8% | 32.8% | -51765.6% | -289620.0% | -345635.7% | -4681200.0% | -1038966.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $493M | $567M | $560M | $340M | $262M | $353M | $288M | $58M | $97M | $27M |
| Cash & Cash Equivalents | $70M | $60M | $149M | $249M | $52M | $153M | $277M | $50M | $92M | $24M |
| Total Liabilities | $85M | $61M | $50M | $32M | $31M | $34M | $32M | $131M | $125M | $47M |
| Total Debt (Short + Long-Term) | $25M | $6M | $6M | $3M | $3M | $1M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $408M | $506M | $511M | $308M | $231M | $319M | $256M | ($73M) | ($28M) | ($20M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive FDMT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms